Corebridge Earnings Preview: Nippon Life Keeps Buying, Shorts Keep Piling In

Corebridge Financial reports Q3 results on November 2, and the setup around the retirement-and-life insurer is unusually split: its largest shareholder is buying stock every single day under a formal plan, while short sellers have been quietly rebuilding positions for six straight weeks.

Nippon Life Insurance holds 29.4% of Corebridge and has filed a Schedule 13D, making it an activist registrant on the SEC's books. That filing, last amended on October 27, shows the stake has grown from 28.4%. The daily purchase disclosures tell the same story: Nippon Life bought shares on each of the ten trading days through October 27, spending roughly $6 million to $14 million per session, all under a pre-arranged 10b5-1 plan. Such plans reduce the informational content of individual trades, but the scale and consistency of the accumulation is still striking. Nippon Life's stake now exceeds 130 million shares, close to a third of the company. As always with 13D/G filings, the disclosed stake is as of the last filing date; positions around the 5% threshold can change without an immediate update.

The short side has also been adding, and the divergence is the central tension ahead of the print. Short interest has climbed roughly 53% since late September to an estimated 16.5 million shares, or 3.2% of the free float. That is still a modest absolute level, but the pace of rebuilding is fast. What the shorts do not have working in their favour is any pressure in the lending market: availability runs at 572%, meaning there are more than five shares available to borrow for every one currently lent out, and the cost to borrow is just 0.53%. Shorts are building positions into the print with minimal friction.

Options positioning has swung sharply more defensive compared with a week ago, which represents a genuine shift from the picture described in the previous ORTEX note. The put/call ratio jumped to 6.37 on October 29, more than two standard deviations above its 20-day average of 5.40, and close to the 52-week high of 6.53. That is a material move in a single session and suggests that options traders are paying more for downside protection than they have at almost any point in the past year.

Analysts have been moving targets higher in the run-up, with TD Cowen, Wells Fargo, Piper Sandler, Mizuho, and Barclays all raising price objectives in October, most clustering around $40. The consensus mean target is $40.42 against a current price of $35.29, implying roughly 14% upside. Barclays made the largest single move, lifting its target from $33 to $39. UBS remains the holdout at Neutral with a $36 target, barely above the current price. The bull case rests on Corebridge's Individual Retirement segment and the benefit of realized bond gains as rates have eased. The bear case points to the same mechanism in reverse: further rate moves or equity market weakness compresses fee income and increases hedging costs, a vulnerability the recent S&P softness has not fully tested.

One additional factor complicates the picture beyond the earnings release itself. ORTEX puts the probability of Corebridge being deleted from the MSCI World at 65%, and from the Russell 1000 and S&P MidCap 400 at 84% and 80% respectively, all tied to the agreed acquisition by Equitable Holdings. Estimated trade dates cluster around December 30. For the MSCI World deletion, ORTEX estimates $673 million of selling by index trackers, equivalent to 4.1 days of normal volume. These are forecasts, not announced decisions, and the dates are estimated. But the acquisition backdrop means the November 2 print is as much a read on deal progress and deal economics as it is on the quarter itself.